1. Generics Bulletin
  2. >>Business

Pfizer And J&J Settle Remicade Antitrust Litigation

Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms

 
• By Dave Wallace

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

Settlement Law Legal Gavel
Pfizer and J&J have settled the Remicade antitrust lawsuit • Source: Alamy

Antitrust litigation between Pfizer and Johnson & Johnson over US contracts and deals for the Remicade (infliximab) brand that were alleged to have been set up so as to dampen biosimilar competition has been dismissed after the companies settled on confidential terms.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.